Journal
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE
Volume 80, Issue 1, Pages 52-72Publisher
WILEY
DOI: 10.1002/jdn.10003
Keywords
clinical trials; inflammation; newborn screening; therapy; very long-chain fatty acids; X-linked adrenoleukodystrophy
Categories
Funding
- Intellectual and Developmental Disabilities Research Centers at the Kennedy Krieger Institute
- Johns Hopkins University [NICHD U54HD079123]
Ask authors/readers for more resources
Adrenoleukodystrophy (ALD) is a rare X-linked disease caused by a mutation of the peroxisomal ABCD1 gene. This review summarizes our current understanding of the pathogenic cell- and tissue-specific roles of lipid species in the context of experimental therapeutic strategies and provides an overview of critical historical developments, therapeutic trials and the advent of newborn screening in the USA. In ALD, very long-chain fatty acid (VLCFA) chain length-dependent dysregulation of endoplasmic reticulum stress and mitochondrial radical generating systems inducing cell death pathways has been shown, providing the rationale for therapeutic moiety-specific VLCFA reduction and antioxidant strategies. The continuing increase in newborn screening programs and promising results from ongoing and recent therapeutic investigations provide hope for ALD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available